


BND-22, A First-in-Class Humanized ILT2-blocking Antibody, Promotes Anti-tumor Immunity and Tumor Regression



Authors

Ilana Mandel, Dana Haves Ziv, Ilana Goldshtein, Tsur Peretz, Dror Alishekevitz, Anna Fridman Dror, Motti Hakim, Sharon Hashmueli, Itay Friedman, Yair Sapir, Rita Greco, Hongjing Qu, Frank Nestle, Dmitri Wiederschain, Lily Pao, Sharad K. Sharma, Tehila Ben Moshe

Correspondence

ilana@biondbio.com

sharad.sharma@sanofi.com

In Brief

BND-22 enhances the activity of innate and adaptive immune cells against tumor cells. BND-22 inhibits ILT2-HLA-G interactions, thus leading to enhanced phagocytosis by macrophages and increased cytotoxic activity of NK cells and CD8 T_{EMRA} T cells against tumor cells.